Steven Vonderfecht

Medicine · Health Sciences

39h-index5.3kcitations162works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Viral gastroenteritis research and epidemiology(39), Animal Virus Infections Studies(17), Cancer, Hypoxia, and Metabolism(14), Radiopharmaceutical Chemistry and Applications(14), Ovarian cancer diagnosis and treatment(12)

Publications162 total

Liver, Gallbladder, and Exocrine Pancreas
Toxicologic Pathology·2024
Supplementary Figure S3 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure S2 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure S3 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Data from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure S2 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure S1 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure Legends and Supplementary Table. from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Data from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure S1 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Supplementary Figure Legends and Supplementary Table. from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2023Open Access
Table S2 from Analysis of Liver Tumor-Prone Mouse Models of the Hippo Kinase Scaffold Proteins RASSF1A and SAV1
2023Open Access
Supplementary Table S1 from AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
2023Open Access
Data from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
2023Open Access
Figures S1-S5 from The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA
2023Open Access
Supplementary Figure 1 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
2023Open Access
Supplementary Table 5 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
2023Open Access
Table S3 from Analysis of Liver Tumor-Prone Mouse Models of the Hippo Kinase Scaffold Proteins RASSF1A and SAV1
2023Open Access
Supplementary Table 2 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
2023Open Access
Supplementary Table 5 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Robert H. Yolken(13), Joseph J. Eiden(5), Richard Lindberg(4), Murielle M. Véniant(4), Pedro J. Beltran(4), David J. Lloyd(3), Clarence Hale(3), Glenn Sivits(3), Xinle Wu(3), Hongfei Ge(3), Bryan D. Lemon(3), Jennifer Weiszmann(3), Jamila Gupte(3), Yang Li(3), Petia Mitchell(3), Elaina Cajulis(3), Brian Belmontes(3), Richard Kendall(3), Robert Radinsky(3), Frank J. Calzone(3)